CA2865823A1 - Basal insulin therapy - Google Patents
Basal insulin therapy Download PDFInfo
- Publication number
- CA2865823A1 CA2865823A1 CA2865823A CA2865823A CA2865823A1 CA 2865823 A1 CA2865823 A1 CA 2865823A1 CA 2865823 A CA2865823 A CA 2865823A CA 2865823 A CA2865823 A CA 2865823A CA 2865823 A1 CA2865823 A1 CA 2865823A1
- Authority
- CA
- Canada
- Prior art keywords
- diabetes
- patient
- insulin
- acting insulin
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims description 47
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title description 183
- 102000004877 Insulin Human genes 0.000 title description 94
- 108090001061 Insulin Proteins 0.000 title description 94
- 229940125396 insulin Drugs 0.000 title description 91
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims abstract description 150
- 108010057186 Insulin Glargine Proteins 0.000 claims abstract description 145
- 229960002869 insulin glargine Drugs 0.000 claims abstract description 142
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 86
- 108010092217 Long-Acting Insulin Proteins 0.000 claims abstract description 69
- 102000016261 Long-Acting Insulin Human genes 0.000 claims abstract description 69
- 229940100066 Long-acting insulin Drugs 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 65
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims description 112
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 78
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 77
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 77
- 230000034994 death Effects 0.000 claims description 65
- 231100000517 death Toxicity 0.000 claims description 65
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 230000010030 glucose lowering effect Effects 0.000 claims description 27
- 239000003538 oral antidiabetic agent Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 239000002131 composite material Substances 0.000 claims description 18
- 229940109239 creatinine Drugs 0.000 claims description 15
- 206010027525 Microalbuminuria Diseases 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 9
- 238000002430 laser surgery Methods 0.000 claims description 9
- 239000005022 packaging material Substances 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 108010089308 Insulin Detemir Proteins 0.000 claims description 5
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 108010050259 insulin degludec Proteins 0.000 claims description 5
- 229960004225 insulin degludec Drugs 0.000 claims description 5
- 229960003948 insulin detemir Drugs 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 201000006370 kidney failure Diseases 0.000 claims description 5
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 claims description 5
- 201000004569 Blindness Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000028208 end stage renal disease Diseases 0.000 claims description 3
- 201000000523 end stage renal failure Diseases 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 177
- 239000008103 glucose Substances 0.000 description 82
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 79
- 208000010125 myocardial infarction Diseases 0.000 description 50
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 48
- 230000002641 glycemic effect Effects 0.000 description 47
- 230000000694 effects Effects 0.000 description 45
- 239000003795 chemical substances by application Substances 0.000 description 33
- 208000013016 Hypoglycemia Diseases 0.000 description 31
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 28
- 229960003105 metformin Drugs 0.000 description 28
- 230000002218 hypoglycaemic effect Effects 0.000 description 27
- 208000006011 Stroke Diseases 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 19
- 239000000902 placebo Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000009467 reduction Effects 0.000 description 18
- 229940100389 Sulfonylurea Drugs 0.000 description 15
- 238000007410 oral glucose tolerance test Methods 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 201000001421 hyperglycemia Diseases 0.000 description 13
- 238000011301 standard therapy Methods 0.000 description 13
- 206010019280 Heart failures Diseases 0.000 description 12
- 230000007774 longterm Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 238000002565 electrocardiography Methods 0.000 description 11
- 230000036210 malignancy Effects 0.000 description 11
- 230000005856 abnormality Effects 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 10
- 238000012423 maintenance Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 229940127017 oral antidiabetic Drugs 0.000 description 9
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 8
- 229940123464 Thiazolidinedione Drugs 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 201000001474 proteinuria Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 4
- 206010001580 Albuminuria Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000009426 cardioembolic effect Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940127208 glucose-lowering drug Drugs 0.000 description 4
- 108091005995 glycated hemoglobin Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
- 229940060975 lantus Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000000250 revascularization Effects 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 150000001467 thiazolidinediones Chemical class 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 238000002266 amputation Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000003293 cardioprotective effect Effects 0.000 description 3
- 230000010036 cardiovascular benefit Effects 0.000 description 3
- 230000007211 cardiovascular event Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229950004994 meglitinide Drugs 0.000 description 3
- 208000037891 myocardial injury Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011272 standard treatment Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000006441 vascular event Effects 0.000 description 3
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000028922 artery disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000014221 sudden cardiac arrest Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- UDIODXADSSQKTM-GUHNCMMLSA-N (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5- Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 UDIODXADSSQKTM-GUHNCMMLSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010049765 Bradyarrhythmia Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 101000929923 Caenorhabditis elegans Acetylcholinesterase 1 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004272 Eragrostis cilianensis Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- -1 LDH Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 208000008376 Pre-Excitation Syndromes Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 235000021236 calorie-restricted diet Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 238000007889 carotid angioplasty Methods 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical group CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001227 hypertriglyceridemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000000290 insulinogenic effect Effects 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940126602 investigational medicinal product Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000001715 left bundle branch hemiblock Diseases 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000009988 metabolic benefit Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940035734 metformin and sulfonylureas Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000007888 peripheral angioplasty Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616768P | 2012-03-28 | 2012-03-28 | |
| US61/616,768 | 2012-03-28 | ||
| US201261619641P | 2012-04-03 | 2012-04-03 | |
| US61/619,641 | 2012-04-03 | ||
| US201261624598P | 2012-04-16 | 2012-04-16 | |
| US61/624,598 | 2012-04-16 | ||
| US201261645909P | 2012-05-11 | 2012-05-11 | |
| US61/645,909 | 2012-05-11 | ||
| US201261701911P | 2012-09-17 | 2012-09-17 | |
| US61/701,911 | 2012-09-17 | ||
| PCT/EP2013/056661 WO2013144273A1 (en) | 2012-03-28 | 2013-03-28 | Basal insulin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2865823A1 true CA2865823A1 (en) | 2013-10-03 |
Family
ID=48044781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865823A Abandoned CA2865823A1 (en) | 2012-03-28 | 2013-03-28 | Basal insulin therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150065421A1 (enExample) |
| EP (1) | EP2830650A1 (enExample) |
| JP (1) | JP2015512908A (enExample) |
| KR (1) | KR20150001757A (enExample) |
| CN (1) | CN104334183A (enExample) |
| AU (1) | AU2013241776B2 (enExample) |
| CA (1) | CA2865823A1 (enExample) |
| HK (1) | HK1201155A1 (enExample) |
| IN (1) | IN2014KN02335A (enExample) |
| MX (1) | MX2014011687A (enExample) |
| RU (1) | RU2014143271A (enExample) |
| SG (1) | SG11201405433XA (enExample) |
| WO (1) | WO2013144273A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017108943A1 (en) * | 2015-12-23 | 2017-06-29 | Sanofi-Aventis Deutschland Gmbh | Cardiac metabolic effect of lantus |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| US20190357853A1 (en) * | 2018-05-24 | 2019-11-28 | Lizheng Shi | Diabetes risk engine and methods thereof for predicting diabetes progression and mortality |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| PH12012502524A1 (en) * | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
-
2013
- 2013-03-28 IN IN2335KON2014 patent/IN2014KN02335A/en unknown
- 2013-03-28 JP JP2015502348A patent/JP2015512908A/ja not_active Ceased
- 2013-03-28 CA CA2865823A patent/CA2865823A1/en not_active Abandoned
- 2013-03-28 CN CN201380028029.4A patent/CN104334183A/zh active Pending
- 2013-03-28 WO PCT/EP2013/056661 patent/WO2013144273A1/en not_active Ceased
- 2013-03-28 US US14/387,791 patent/US20150065421A1/en not_active Abandoned
- 2013-03-28 EP EP13713425.0A patent/EP2830650A1/en not_active Withdrawn
- 2013-03-28 AU AU2013241776A patent/AU2013241776B2/en not_active Expired - Fee Related
- 2013-03-28 KR KR20147028987A patent/KR20150001757A/ko not_active Withdrawn
- 2013-03-28 RU RU2014143271A patent/RU2014143271A/ru not_active Application Discontinuation
- 2013-03-28 SG SG11201405433XA patent/SG11201405433XA/en unknown
- 2013-03-28 HK HK15101611.0A patent/HK1201155A1/xx unknown
- 2013-03-28 MX MX2014011687A patent/MX2014011687A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150001757A (ko) | 2015-01-06 |
| RU2014143271A (ru) | 2016-05-20 |
| SG11201405433XA (en) | 2014-10-30 |
| WO2013144273A1 (en) | 2013-10-03 |
| AU2013241776A1 (en) | 2014-10-16 |
| CN104334183A (zh) | 2015-02-04 |
| IN2014KN02335A (enExample) | 2015-05-01 |
| EP2830650A1 (en) | 2015-02-04 |
| HK1201155A1 (en) | 2015-08-28 |
| US20150065421A1 (en) | 2015-03-05 |
| JP2015512908A (ja) | 2015-04-30 |
| MX2014011687A (es) | 2015-05-11 |
| AU2013241776B2 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosenstock et al. | One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target | |
| Janez et al. | Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group | |
| ES2604359T3 (es) | Uso de insulina glargina para reducir o prevenir la morbilidad y mortalidad cardiovascular en pacientes pre-diabéticos | |
| RS61403B1 (sr) | Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom | |
| Philis-Tsimikas | Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control | |
| AU2013241776B2 (en) | Basal insulin therapy | |
| Landgraf et al. | Therapy of type 2 diabetes | |
| Graveling et al. | Does hypoglycaemia cause cardiovascular events? | |
| Mulla et al. | Prediabetes: a benign intermediate stage or a risk factor in itself? | |
| US20210000792A1 (en) | Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus | |
| Class et al. | Patent application title: BASAL INSULIN THERAPY Inventors: Peter Johnston (Bridgewater, NJ, US) Hertzel Gerstein (Hamilton, CA) Hertzel Gerstein (Hamilton, CA) | |
| Azeez | Present State and Perspectives of Type 2 Diabetes Management | |
| Stefanova et al. | Hypoglycaemia: causes, risk factors and pathophysiology | |
| Das et al. | Pathophysiology and Clinical Therapeutic Aspects of Diabetes | |
| Hudson et al. | Diabetes in older adults | |
| Valdez et al. | Long term evaluation of intensive insulin therapy in patients with type 2 diabetes mellitus | |
| Jang et al. | The Early Detection and Managements of Euglycemic Diabetic Ketoacidosis Based on a Rapid Response System: Two Case Reports | |
| Hiremath | Handbook Of Perioperative Care Of Adult Diabetes Patients: Diabetes Care–Before, During And After Surgery | |
| Sia | Pharmacologic management of diabetes in older adults | |
| Gase et al. | 66. TYPE 2 DIABETES MELLITUS | |
| Wong et al. | Navigating Hypoglycemia in Diabetes Care: Clinical Management Strategies and Glucagon Treatment Options | |
| Barsh et al. | A Case Report of Anaphylactic Shock to Tirzepatide | |
| Baby et al. | Prescribing pattern of antidiabetic drugs for type 2 diabetic in tertiary care teaching hospital | |
| SINGH et al. | The Glycemic Efficacy and Safety Profile of Gliptins: Updated Data in 2020 | |
| Zhen et al. | Diabetic Emergencies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20190328 |